.png)
Monica Rossleigh
Sydney Children’s Hospital , AustraliaPresentation Title:
Factors to consider prior to administering radioactive iodine therapy in differentiated thyroid cancer
Abstract
Following total thyroidectomy, information regarding surgical and histological findings, molecular marker status and the analysis of risk assessment using ATA (American Thyroid Association) criteria determines the need for I-131 therapy. The potential complications of this therapy need to be considered and a risk/benefit analysis is required before proceeding to administering this treatment. It is also essential to recognize when radioactive iodine refractory disease is present so that alternative treatment such as TKI (Tyrosine Kinase Inhibitor) therapy can be considered. TKI therapy can not only be utilized in the treatment of metastatic thyroid cancer but can also be given to re-differentiate the disease to enable further radioactive iodine therapy to be given for disease control.
Biography
Monica Rossleigh is a Nuclear Medicine Physician with a special interest in the management of benign and malignant thyroid disease. She is an Advisory Board member of the Thyroid Head and Neck Foundation based in New York and is an active participant of TIRO (Thyroid International Recommendations Online) and their weekly online forum TIROxMDS, the sessions of which are stored and available on YouTube. She has 98 scientific journal publications and attends and presents at various international conferences.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801 USA
Mail us at
Program Enquiry
oncology@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
oncology@scientexconferences.com
Our Social Presence
Call us at
USA :(+1) 323 677 0554